AFMK

Research use only, not for human use.

AFMK is an active metabolite of Melatonin with antioxidant and free radical scavenging activity. AFMK is a modulator of apoptosis and improves the anti-tumor effect of Gemcitabine in PANC-1 cells.

AFMK is an active metabolite of Melatonin with antioxidant and free radical scavenging activity. AFMK is a modulator of apoptosis and improves the anti-tumor effect of Gemcitabine in PANC-1 cells.(In Vitro):In PANC-1 cell, AFMK in combination with Gemcitabine increases the inhibition of the production of HSP70 from 0.47 (Gemcitabine alone) to 0.13 (10 nM AFMK), 0.08 (0.1 nM AFMK) and 0.01 (0.001 nM AFMK). AFMK pretreatment significantly inhibits DNA damage and shows a very high hydroxyl radical scavenging potential with an IC50 of 338.08 nM.(In Vivo):In male C57BL mice, AFMK (10 mg/kg; i.p.) significantly reverses radiation-induced decline in the total antioxidant capacity of plasma. Pretreatment of AFMK shows a significantly lower value of comet tail length and % DNA in tail.

AFMK is one of the metabolites of melatonin and can be formed by both enzymatic or pseudoenzymatic and nonenzymatic metabolic pathways.AFMK pretreatment significantly inhibits DNA damage. AFMK shows a very high level of in vitro hydroxyl radical scavenging potential which was measured by an electron spin resonance (ESR) study. IC50 values resulting from ESR analysis was 338.08 nM. AFMK, a melatonin metabolite, is a sparingly investigated biogenic amine. AFMK administered to PANC-1 in combination with Gemcitabine inhibits the production of HSP70 and cIAP-2 as compared to the results obtained with Gemcitabine alone.Western Blot Analysis Cell Line:Human pancreatic carcinoma cell line (PANC-1)Concentration:0.001, 0.1, 10, 1000 nMIncubation Time:Result:Augmented the inhibitory effects on HSP70 expression from 0.47 (Gemcitabine alone) to 0.13 (10 nM AFMK), 0.08 (0.1 nM AFMK) and 0.01 (0.001 nM AFMK).

AFMK is a potent antioxidant in vivo. AFMK significantly reverses radiation-induced decline in the total antioxidant capacity of plasma in mice. Animal Model:Male C57BL mice 8 wk of age Dosage:10 mg/kg body weight Administration:Intraperitoneal injection Result:Radiation-induced decline in the total antioxidant capacity of plasma was significantly reversed in AFMK pretreated mice. AFMK-pretreated irradiated groups showed a significantly lower value of comet tail length and % DNA in tail.

Acetyl-N-formyl-5-methoxykynurenamine | Formyl-N-acetyl-5-methoxykynurenamine

Apoptosis

Apoptosis

Human Endogenous Metabolite|Antioxidant|Free radical scavengers|Apoptosis

——

——

52450-38-1

264.28

C13H16N2O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (189.19 mM)

O=CNC1=CC=C(OC)C=C1C(=O)CCNC(=O)C

——

(-20℃)

With Ice Pack

≥ 2 years